
    
      The TPV is indicated for use in patients with previous undergone replacement of bioprosthetic
      valve or conduit due to either pulmonary valve atresia, stenosis, regurgitation or a
      combination of them and present with dysfunctional right ventricular ourflow tract (RVOT)
      requiring treatment for severe pulmonary regurgitation and/or RVOT conduit obstruction.
      Consecutive subject data should be collected at discharge, 1, 3, 6 month, and 1-5 years post
      TPV implantation.
    
  